![Simon Barnett on Twitter: "We think GRAIL's methylation-based approach is unique and powerful. This approach is low cost and enables detection of early stage disease. Not sure what this means? That's okay, Simon Barnett on Twitter: "We think GRAIL's methylation-based approach is unique and powerful. This approach is low cost and enables detection of early stage disease. Not sure what this means? That's okay,](https://pbs.twimg.com/media/Eic0pf5XgAAxUDn.png)
Simon Barnett on Twitter: "We think GRAIL's methylation-based approach is unique and powerful. This approach is low cost and enables detection of early stage disease. Not sure what this means? That's okay,
![Grail's cancer blood test tracks down over 50 types of early-stage disease in study | Fierce Biotech Grail's cancer blood test tracks down over 50 types of early-stage disease in study | Fierce Biotech](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/fiercebiotech/1585681028/blood-group-2781421_1280.jpg/blood-group-2781421_1280.jpg?VersionId=bEHgq6Zr0Oz6V52ab5GcBx8AyTcgUMP6)
Grail's cancer blood test tracks down over 50 types of early-stage disease in study | Fierce Biotech
![Illumina completes $8B Grail acquisition, companies remain separate amid European review - MassDevice Illumina completes $8B Grail acquisition, companies remain separate amid European review - MassDevice](https://www.massdevice.com/wp-content/uploads/2020/09/Illumna-Grail.jpg)
Illumina completes $8B Grail acquisition, companies remain separate amid European review - MassDevice
![Grail, Quest Diagnostics to collaborate on Galleri multi-cancer early detection blood test - MassDevice Grail, Quest Diagnostics to collaborate on Galleri multi-cancer early detection blood test - MassDevice](https://www.massdevice.com/wp-content/uploads/2021/02/GRAIL_logo-1.jpg)